Imaging Alterations in Endocannabinoid Metabolism in Schizophrenia
Imaging Alterations in Endocannabinoid Metabolism in Schizophrenia
批准号:
8934154
负责人:
Romina Mizrahi
金额:
$14.71万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-25 至 2016-08-31
关键词:
AnimalsAntipsychotic AgentsBindingBrainCNR1 geneCannabinoidsCannabisCarbonCerebrospinal FluidCerebrovascular CirculationChemicalsClinicalClinical ResearchCognitive deficitsCollaborationsComplexCorpus striatum structureDataDiseaseDopamineDoseDrug KineticsEconomicsEndocannabinoidsEnzymesEpidemiologic StudiesEpidemiologyEtiologyExhibitsFamilyFutureGatekeepingHealthHeterogeneityHumanHuman VolunteersHydrolysisImageIncidenceIndividualInvestigationJointsKineticsLabelLeadLifeLinkMRI ScansMeasuresMetabolismModelingMolecularNeurotransmittersOutcome MeasureParticipantPathway interactionsPatient CarePatientsPharmacodynamicsPlasmaPlayPopulationPositron-Emission TomographyPrefrontal CortexPreventionPropertyPsychopathologyPsychotic DisordersRadioactivityRadiochemistryRecording of previous eventsRegulationReportingReproducibilityResearchResolutionRiskRisk FactorsRoleSafetySchizophreniaSeveritiesSignal PathwaySignal TransductionSiteSpecificityStressSymptomsSystemTestingTherapeutic AgentsTimeTissuesTracerVolunteer Groupanandamidebasecannabinoid receptorclinical infrastructurecognitive functiondensitydosimetryendogenous cannabinoid systemfatty acid amide hydrolasehealthy volunteerin vivoindexinginhibitor/antagonistmarijuana usemolecular imagingneurochemistryneuroimagingneurotransmitter releasenovelnovel strategiesnovel therapeutic interventionnovel therapeuticspresynapticpsychotic symptomsradioligandradiotracerreceptor expressionsocialuptakeyears lived with disability
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): While the role of dopamine in positive symptoms of schizophrenia (SCZ) is well established, it is increasingly recognized that cannabinoid signaling may also play a key role. Epidemiological studies have detected a twofold increase in the incidence of SCZ with early cannabis use, identifying it as a major trigger for the disease and thus providing the first link between cannabinoids and SCZ. The most studied of endocannabinoids (eCBs), anandamide (AEA), acts on the presynaptic CB1 receptors to modulate the release of neurotransmitters. Dramatic elevations of AEA were detected in cerebrospinal fluid of patients with SCZ in the midst of a psychotic episode, which normalize after psychosis resolution. Levels of AEA in the brain are tightly regulated through hydrolysis by the fatty acid amide hydrolase (FAAH) enzyme. FAAH therefore sets the tone of the eCB system. [11C]CURB, a carbon-11-labelled form of the potent irreversible FAAH inhibitor URB694, has recently been synthesized by our CAMH radiochemistry team and characterized for positron emission tomography (PET) imaging. The tracer exhibits high brain uptake, regional distribution that reflects known FAAH density, and excellent pharmacodynamic and pharmacokinetic properties, as established in animal studies. Furthermore, PET imaging in healthy volunteers (HV) was carried out to establish proof-of- concept, test-retest reproducibility
and full body dosimetry, and to optimize kinetic modeling for [11C]CURB quantification. As the first radiotracer capable of assessing FAAH enzyme in-vivo, [11C]CURB goes beyond quantifying CB1 receptor expression by providing for the first time an index of AEA/FAAH in the living brain. We aim to measure FAAH in vivo by using [11C]CURB PET in antipsychotic-naive patients with SCZ. We hypothesize that [11C]CURB binding in the striatum and dorsolateral prefrontal cortex will be significantly lower in SCZ, as compared to HV. Additionally, we aim to explore the relation between regional FAAH levels and psychopathology and cognitive deficits in SCZ. Thirty-four participants (17 in SCZ and 17 in HV group) will undergo a 60 min [11C]CURB PET scan using a high-resolution research tomograph (HRRT). As previously established, the kinetics of [11C]CURB can be described with an irreversible two-tissue compartment model using metabolite-corrected [11C]CURB radioactivity in arterial plasma as input function, providing the reliable outcome measure ?k3. High resolution Magnetic Resonance Imaging (MRI) scans will provide an anatomical correlation needed to quantify regional tracer distribution in the PET image, as well as to measure regional cerebral blood flow. The proposed research will be the first exploration of changes in eCB signaling in a living brain evaluating for the first time AEA metabolism in SCZ. Our research is important since it may elucidate the neurochemical mechanism behind the role of cannabis in the onset of SCZ. This conceptual breakthrough would have significant impact on the field of psychosis, providing a new approach to treatment and prevention of SCZ.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1111/adb.12872
发表时间:
2021-01
期刊:
Addiction biology
影响因子:
3.4
作者:
[Jacobson MR, Watts JJ, Da Silva T, Tyndale RF, Rusjan PM, Houle S, Wilson AA, Ross RA, Boileau I, Mizrahi R]
通讯作者:
Mizrahi R
DOI:
10.1016/j.pnpbp.2020.110096
发表时间:
2021-03-02
期刊:
Progress in neuro-psychopharmacology & biological psychiatry
影响因子:
5.6
作者:
[Garani R, Watts JJ, Mizrahi R]
通讯作者:
Mizrahi R
Imaging Alterations in Endocannabinoid Metabolism in Clinical High Risk and First Episode Psychosis
-
批准号:10707675
-
项目类别:
-
资助金额:$44.36万
-
财政年份:2022
-
负责人:Romina Mizrahi
-
依托单位:
Imaging Alterations in Endocannabinoid Metabolism in Clinical High Risk and First Episode Psychosis
-
批准号:9765411
-
项目类别:
-
资助金额:$44.37万
-
财政年份:2017
-
负责人:Romina Mizrahi
-
依托单位:
Imaging Alterations in Endocannabinoid Metabolism in Clinical High Risk and First Episode Psychosis
-
批准号:10288012
-
项目类别:
-
资助金额:$44.37万
-
财政年份:2017
-
负责人:Romina Mizrahi
-
依托单位:
Imaging Alterations in Endocannabinoid Metabolism in Schizophrenia
-
批准号:8816894
-
项目类别:
-
资助金额:$14.66万
-
财政年份:2014
-
负责人:Romina Mizrahi
-
依托单位:
Imaging Neuroinflammation in Clinical high risk and Schizophrenia
-
批准号:8629160
-
项目类别:
-
资助金额:$26.27万
-
财政年份:2014
-
负责人:Romina Mizrahi
-
依托单位:
Imaging Neuroinflammation in Clinical high risk and Schizophrenia
-
批准号:9204428
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2014
-
负责人:Romina Mizrahi
-
依托单位:
Imaging Neuroinflammation in Clinical high risk and Schizophrenia
-
批准号:8792554
-
项目类别:
-
资助金额:$26.2万
-
财政年份:2014
-
负责人:Romina Mizrahi
-
依托单位:
海外基金